Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Petros Benias

Gastroenterology New, NY Medical Doctor

NPI 1649429077 CMS profile 1295800

10 Union Sq 2G, New, NY 10003

Open in the dashboard

General payments

$130,323

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Petros Benias of New, NY is reported in the CMS Open Payments database as having received $130,323 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,740 38
2024 General $17,500 27
2023 General $34,820 47
2022 General $13,688 18
2021 General $12,174 29
2020 General $22,541 19
2019 General $24,861 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Petros Benias
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Petros Benias were reported at $4,740. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Petros Benias Gastroenterology median Middle half National median
2019 $24,861 $417 $126–$1,100 $163
2020 $22,541 $224 $74–$624 $114
2021 $12,174 $352 $106–$1,054 $132
2022 $13,688 $448 $129–$1,270 $149
2023 $34,820 $533 $150–$1,390 $160
2024 $17,500 $605 $160–$1,606 $164
2025 $4,740 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $50,387 108 payments
  2. FUJIFILM Medical Systems USA, Inc. $24,917 21 payments
  3. Micro-tech Endoscopy USA, Inc. $21,324 28 payments
  4. Apollo Endosurgery US Inc $14,567 22 payments
  5. Covidien LP $6,226 4 payments
  6. Olympus Corporation of the Americas $5,408 6 payments
  7. Creo Medical Inc. $4,283 5 payments
  8. Olympus America Inc. $891 13 payments
  9. Medtronic, Inc. $838 8 payments
  10. Olympus Corporation $644 1 payment
  11. Other $840 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $68,900 32 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,510 11 payments
  3. Travel and Lodging $10,870 28 payments
  4. Food and Beverage $9,266 137 payments
  5. Royalty or License $4,277 19 payments
  6. Grant $500 1 payment
Products named General payments · program years 2019–2025
  1. ESD - Core Endoscopy $15,800 10 payments
  2. X-Tack Endoscopic HeliX Tacking System $9,722 10 payments
  3. Overstitch $9,546 13 payments
  4. GoldKnife $8,229 3 payments
  5. General - Therapies $6,156 6 payments
  6. Olympus EMR & ESD Devices $5,549 10 payments
  7. OverStitch Endoscopic Suturing System $5,013 8 payments
  8. OverStitch Endoscopic Suturing System Sx $4,756 3 payments
  9. RESOLUTION CLIP $3,861 6 payments
  10. ACQUIRE $3,762 2 payments
  11. Other $19,747 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

20

Median for Gastroenterology: 569

Drug cost

$226

Median for Gastroenterology: $104,976

Branded share of claims

0%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 20 $226

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$65,729

Medicare's payments for the services billed

Medicare patients

218

Average age 74

Services billed

557

105 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 48%
Ischemic heart disease 46%
Chronic kidney disease 36%
Atrial fibrillation 32%
Heart failure 30%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record